Aug 2026· Cell Reports· Vol 45, pp. 117846 - 117846· 0 citations· 99 references
Medicine
Abstract
SUMMARY Ewing sarcoma (EwS) is characterized by chimeric fusions such as EWSR1::FLI1. Chromosome gain or loss is prevalent in EwS, and this chromosome instability (CIN) phenotype correlates with poor treatment outcomes. We previously showed that CENP-A, a centromere-specific histone H3 variant, interacts with EWSR1 via its SYGQ2 motif, an interaction extending to the EWSR1::FLI1 fusion protein. CENP-A is highly expressed in EwS cells, driven by EWSR1::FLI1. EwS cells exhibit significant CIN, mitigated by depleting EWSR1::FLI1 or CENP-A, and frequently assemble neocentromeres. Using CENP-A ChIP-seq, we identify neocentromere-associated DNA sequences, and ChIP assays confirm EWSR1::FLI1 binds these sequences, suggesting EWSR1::FLI1 recruits CENP-A to drive neocentromere assembly. Notably, overexpressing EWSR1::FLI1, but not CENP-A, induces neocentromeres in non-EwS cells. These neocentromeres likely produce dicentric chromosomes, explaining the high incidence of chromosome bridges and chromoplexy underlying the CIN phenotype in EwS.
This project suggests that the EWSR1 LCD is involved mechanistically in the binding of consecutive µsats through LCD-LCD interactions, highlighting a novel mechanistic contribution of this domain to EWSR1::FLI1 function.
Caleb J. Frye, R. Zhou, Lexis R. Rice et al.· Cancer Research· 0 citations
It is revealed that EWSR1::FLI1 possesses a key pioneer factor property, efficiently targeting its binding site within nucleosomes, and that full-length EWSR1::FLI1 binding shifts to preferentially target GGAA repeats, even on motifs that bind a single EWSR1::FLI1 protein.
Ruo-Wen Chen, R. Zhou, E. J. Tokarsky et al.· bioRxiv· 0 citations
New insights are revealed into how EWSR1::FLI1 binds to DNA motifs in chromatin and it is suggested that the EWSR1 LCD may contribute to both altered sequence-specific DNA binding and nucleosome engagement.
Ruo-Wen Chen, R. Zhou, E. J. Tokarsky et al.· Cancer Research· 0 citations
The identification of the splicing factor RBM39 as a vulnerability in ES is supported by the extraordinary sensitivity of these tumors to monotherapy with RBM39 degrader indisulam, highlighting the potential of this approach as a novel and promising therapeutic strategy for Ewing sarcoma.
Irene Cuervas, Sophie Bonnal, Evelyn Andrades et al.· bioRxiv· 0 citations
Ewing sarcoma tumors are defined by chromosomal translocations fusing
EWSR1
to ETS family genes, most commonly
FLI1
. The resulting EWS::FLI1 fusion oncoprotein drives tumorigenesis while simultaneously generating unique metabolic and molecular dependencies that may be exploited for Ewing sarcoma–specific therapi...
Mian T. Mhindu, S. Koppenhafer, Mason G. Lyons et al.· Frontiers in Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.